At Syndivia, we are dedicated to advancing treatment options for cancer patients through our innovative GeminiMab™ Technology. This platform enables the creation of site-specific antibody-drug conjugates (ADCs) in the hinge region, ensuring optimal drug-to-antibody ratios (DAR), including the unique site-specific DAR 1. Our approach leverages these targeted ADCs' distinct properties to significantly enhance antitumor efficacy, offering a powerful and well-tolerated therapeutic option for cancer patients.